Hims & Hers will sell real Ozempic in deal with Novo Nordisk

Hims & Hers will begin selling branded Novo Nordisk GLP-1s (Wegovy and Ozempic) after settling a patent dispute, and HIMS shares jumped up to ~52% in pre-market trading. Novo Nordisk agreed to drop its lawsuit and Hims will stop advertising compounded GLP-1 offerings, with branded products slated to appear on Hims’ platform later this month. The deal removes a major legal overhang for HIMS, opens a clear revenue pathway from branded GLP-1 distribution, and warrants monitoring of patient transitions, pricing/margins, and competitive dynamics with Eli Lilly.

Analysis

Converting a previously opaque demand stream into a sanctioned branded channel materially alters margin capture and price realization across the GLP-1 stack. Expect manufacturers' gross revenue per prescription to rise and leakage to compounded suppliers to fall, but the conversion will be phased over multiple refill cycles — think measurable impact on weekly shipment volumes within 4–12 weeks and on reported quarterly revenues in 1–2 quarters.

The biggest indirect competitive lever is distribution economics: telehealth platforms can accelerate trial and reduce frictional churn, advantaging suppliers who can guarantee supply and favorable channel economics. That favors players with scale manufacturing and tight supply chains while increasing short-term downside for smaller innovators or entrants reliant on retail/physician-first models; watch API and fill–finish utilization rates as a choke-point for share shifts over the next 6–12 months.

Regulatory and payer responses are the highest-probability tail risks that can reverse momentum: expect accelerated utilization management from PBMs and payers within 3–9 months and potential scrutiny of telehealth prescribing practices over 6–18 months. Market price action will likely overshoot; retail excitement can re-rate distribution partners faster than underlying prescription economics justify, creating actionable short-term mean-reversion opportunities ahead of slower fundamental uptake.

Key Decisions for Investors

• Long NVO (stock or 12-month call spread): Buy NVO 12-month call spread sized 2–4% notional to capture branded ASP and margin tailwinds; target 20–35% upside if U.S. branded channel share rises measurably in next two quarters. Risk: manufacturing/payer pushback; cut to flat if sequential U.S. shipment growth stalls for two consecutive quarters.
• Short HIMS (equity or 1–3 month put spread): Initiate a tactical short after intraday volatility cools—use 1–3 month put spread to limit downside exposure. Target 30–40% downside from current inflated levels driven by retail euphoria; stop-loss at +25% from entry given headline-driven reversals.
• Pair trade (Long NVO / Short LLY, 6–12 months): Size as a market-neutral pair to express expected re-acceleration for incumbents with guaranteed supply vs. share gains for late entrants. Aim for 15–25% relative outperformance; risk that supply constraints or clinical differentiation re-accelerate LLY's share (monitor weekly shipment and inventory data).
• Tactical play on payers/retailers (CVS or CI, 3–6 months): Buy 3–6 month call spreads on CVS or CI (small position) to capture incremental dispensing/rebate flow; cap position due to risk of payer negotiation compressing margins. Take profits on a 15–20% move; cut exposure if public PBM guidance signals tighter utilization controls.